Adecto Pharmaceuticals is a small, preclinical stage company, developing the first targeted therapy against ADAM8-positive cancers and a companion diagnostic to identify patients who can benefit from it. ADAM8 is a cell surface, novel target protein, which drives aggressive tumor growth and spread, and poor patient survival. It is implicated in various solid tumors, including those of the breast, stomach, colon, liver and pancreas. Our current focus is on triple-negative breast cancer as the first indication with plans to expand to other cancers in the future. Our therapeutic is a first-in-class, monoclonal antibody that specifically and simultaneously inhibits 2 extracellular ADAM8 domains, which together drive its cancer promoting functions. Our diagnostic is an immunohistochemistry-based assay for tumor biopsies. Based on current knowledge of ADAM8 expression in multiple cancers, and their reported prevalence, we estimate globally ~2M patients could benefit from our products.
Adecto Pharmaceuticals is presenting as part of the NIH Innovation Zone.